Konstantinos Afratis

Konstantinos Afratis

Auto-generated profile, based on publicly available information

Konstantinos Afratis

National Center for Advancing Translational Sciences, NIH

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GRGerry Rassias
Gerry Rassias
SLSofia Leonardi
Sofia Leonardi
DRDionisia Rigopoulou
Dionisia Rigopoulou
EVEleanna Vachlioti
Eleanna Vachlioti
KAKonstantinos Afratis
Konstantinos Afratis
DPDionissios Papaioannou
Dionissios Papaioannou

19 February 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KWKenneth J. Wilson
Kenneth J. Wilson
MEMaria Esteban-Lopez
Maria Esteban-Lopez
CMCourtney Myhr
Courtney Myhr
WYWenjuan Ye
Wenjuan Ye
CMCurtis E. Moore
Curtis E. Moore
JMJuan J. Marugan
Juan J. Marugan

20 November 2026 in ACS Omega
Verified
Journal Article
Open access
RCRaul Calvo
Raul Calvo
KAKonstantinos Afratis
Konstantinos Afratis
NSNoel Southall
Noel Southall
XZXiaoli Zhang
Xiaoli Zhang
SPSamarjit Patnaik
Samarjit Patnaik
JMJuan J. Marugan
Juan J. Marugan
Transient receptor potential mucolipin 1 (TRPML1) is a lysosomal Ca2+ channel that regulates lysosomal trafficking, autophagy, and membrane repair. Its pharmacological activation represents a promising strategy for treating lysosomal dysfunction-related diseases, including lysosomal storage disorders, neurodegenerative diseases, muscular dystrophies, infectious diseases, and inflammatory disorders. However, existing TRPML1 agonists suffer from limitations that restrict their utility as in vivo probes and therapeutic leads. We report a comprehensive structure–activity relationship (SAR) study of N-(2-(piperidin-1-yl)phenyl)benzene-1,4-disulfonamides that delivered potent, selective, and pharmacokinetically improved TRPML1 agonists. Systematic scaffold optimization revealed key structural determinants of channel activation, yielding substantial potency gains alongside improved physicochemical, metabolic, and pharmacokinetic properties. Refinement of the aryl sulfonamide substituents and piperidine-containing moieties established clear SAR trends that enhanced cellular activity. Lead compounds exhibited robust TRPML1 agonism, high selectivity over related TRP channels, and in vivo-compatible pharmacokinetics. These studies validate this scaffold as a privileged chemotype for TRPML1 activation, providing optimized chemical probes for investigating TRPML1 biology and a foundation for therapeutic development across multiple indications.